
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Highlights include: Eliminating dangerous drug abbreviation habits, easy-to-use online drug interaction checkers, and more.






